

The Characteristics of Chronic Heart Failure in Rheumatoid Arthritis

Review Article

Harutyun S. Hovhannisyan*

Yerevan State Medical University, Department of Internal Diseases #1

Abstract: In recent times there is an emerging evidence about the increased risk of cardiovascular disease (CVD) and rheumatic conditions. This review has been focused on the multiple relationships between rheumatoid arthritis (RA) and heart failure (HF) features.

Cardiovascular (CV) system involvement is an extra-articular complication of RA and is a major cause of morbidity and mortality. All heart structures may be affected in RA and different clinical manifestations may be seen.

HF is a complex clinical syndrome which represents universal end-stage of nearly every form of heart disease and has a poor prognosis. Patients with RA have almost 2-fold higher risk of HF development than non RA-subjects and this high risk is not explained entirely by traditional CV risk factors. RA patients with HF appear to have a more subtle presentation of HF, compared to HF patients without RA, while mortality from HF is significantly higher. In RA HF mostly is manifested by diastolic dysfunction (DD) which is revealed by echocardiography. In general, brain natriuretic peptide (BNP) is an important clinical and prognostic marker of HF, but there are no final data concerning its screening value in RA-subjects.

Nevertheless, up to date HF is still being poorly revealed in most RA-patients, especially on early stages of the disease, which leads to HF treatment delay, thus contributing to mortality.

These findings emphasize the role and need of further larger studies in this field, which will bring to early identification and treatment of RA-subjects with HF and a decrease in mortality rates.

Keywords: Chronic heart failure, Rheumatoid arthritis, Risk factors, Brain natriuretic peptides, Echocardiography.

INTRODUCTION

In recent years there is a great attention towards the relationships between cardiovascular disease (CVD) and rheumatic diseases. The increased risk of CVD has been described extensively in rheumatoid arthritis (RA) [1-4], systemic lupus erythematosus (SLE) [5-7], ankylosing spondylitis (AS) and psoriatic arthritis [8-13].

RA is a systemic disease of unknown origin, which is characterized by chronic inflammatory process and mainly leading to small and large joints synovial membrane destruction. The prevalence of RA is 0.5-1% in general population of adults and women at reproductive age are 2-3 times higher affected by the disease [14, 15]. RA is an invalidating disease which is associated with life quality changes and decrease in mean duration of life [16]. Furthermore, there is observed high incidence of early mortality after the onset of disease, which particularly can be explained by infective, digestive, renal or pulmonary complications and lung neoplasia (mainly lung cancer and non-Hodgkin lymphoma [17].

Cardiovascular (CV) system involvement is an extra-articular complication of RA and is a major cause of morbidity and mortality. All heart structures may be affected by various pathogenic mechanisms and respectively different clinical manifestations may be seen: valvular heart disease, pulmonary hypertension, rhythm and conduction disturbances, myocarditis/pericarditis, myocardial fibrosis, coronary heart disease (CHD) up to myocardial infarction (MI), and particularly, heart failure (HF) [18].

Moreover, RA is suggested to be an independent risk factor for CHD development similar to type 2 diabetes mellitus (DM) [19].

HF in RA

HF is a complex clinical syndrome which represents universal end-stage of nearly every form of heart disease and has a poor prognosis [20, 21].

Patients with RA have almost 2-fold higher risk of HF development than those without RA and this high risk is not fully explained by traditional CV risk factors [22].

Furthermore, RA patients with HF appear to have a more subtle presentation of HF, compared to HF patients without RA, while mortality from HF is significantly higher [23].

*Address correspondence to this author at the Yerevan State Medical University, Department of Internal Diseases #1, 2 Koryun St, Yerevan 0025, Yerevan, Armenia; Tel: +374 91 360772; Fax: (+374 10) 58 25 32; E-mail: hovhannisyan84@gmail.com

The increased risk of developing HF in RA is well described [24-26]. In particular, in a population-based incidence cohort of patients with RA over a 40-year period there was observed a higher incidence of HF among patients with RA compared with a cohort of non-RA patients. After adjusting for age, sex, CHD, and traditional CV risk factors, the risk of developing HF (defined by Framingham Heart Study Criteria) in patients with RA was almost twice that of non-RA patients (HR 1.87, 95% CI 1.47-2.39), with an increase in cumulative incidence observed over time. Though higher incidence of HF was seen among all age groups, it tended to be increased in women compared with men (relative risk [RR] 1.9, 95% CI 1.4-2.5 vs RR 1.3 95% CI 0.9-2.0) [22].

Compared with the general population, HF in patients with RA seems to be more frequently associated with diastolic dysfunction (DD) [27, 28]. After adjusting for age, sex, and history of CHD, patients with RA were twice as likely to have preserved LV ejection fraction (EF) (odds ratio [OR] 1.90, 95% CI 0.98-3.67) [29]. When HF with reduced EF does occur in patients with RA, it is seen much more frequently in men (HR 3.7, 95% CI 1.8-7.7) [25]. DD is a predictor for incident HF independent of the traditional CV risk factors (HR 1.81, 95% CI 1.01-3.48) [31, 33]. Echocardiographic findings of DD were associated with an increase in all-cause and cardiac mortality [32-34].

Risk Factors of CVD and RA

Risk factors of HF range very widely from lifestyle factors to comorbidities, medications, laboratory and genomic markers, *etc.* [35-38]. However, the main risk factors include hypertension, CHD, diabetes mellitus, and obesity. Hypertension and CHD are the most common and strongest risk factors conferring a 2-3 times increased risk [39]. HF risk increases with age and male gender is associated with a higher risk [40]. Valvular heart disease, low physical activity, obesity, coffee consumption, increased salt intake, and low socioeconomic status all have been associated with increased risk [40, 41]. Excessive alcohol intake increases BP, but light-to-moderate consumption lowers the risk of HF [42-44]. Smoking promotes several CVD risk factors associated with HF [40, 45]. Dyslipidaemia, renal dysfunction, some medications (e.g. chemotherapeutic agents) and comorbidities (anaemia, microalbuminuria, increased heart rate, *etc.*) are also associated HF [46-49].

Risk factors for RA include female sex, a positive family history, older age, silicate exposure, and smoking [50-52]. Consumption of more than 3 cups of coffee daily (particularly decaffeinated coffee) also may contribute to RA development [53].

Thus, age, smoking and coffee consumption are the same risk factors for the development of both HF and RA.

The increased risk of CVD in RA patients is not entirely explained by an increased incidence of the traditional CV risk factors. Some traditional risk factors in RA may even play a paradoxical role [24, 54, 55].

The influence of age on the CV risk in patients with RA may be even greater than for the general population. In a population-based inception cohort of patients with RA with no prior CVD history the effect of age on CVD risk was almost twice that in the general population in men and more than twice that in women. The impact of age on CVD risk in seronegative patients and in subjects younger than 50 years was similar to that seen in the general population [56].

The prevalence of smoking is higher in patients with RA, but this risk factor alone is unlikely to account for the increased CVD risk [55, 57, 58].

DM, arterial hypertension, dyslipidaemia, and alcohol use/abuse have not been described more frequently in patients with RA when compared with non-RA subjects [22-24, 58].

Obesity and lipids seem to play a paradoxical role in CVD risk in patients with RA, with a lower BMI and lower total cholesterol associated with higher CV risk [58, 59]. Patients with RA with a higher BMI have lower mortality rates than that seen in thinner patients independent of RA onset, age, duration, and smoking status [60].

HDL, LDL and total cholesterol levels may be reduced in patients with untreated RA and later increase with suppression of inflammation via treatment, although the increase in LDL cholesterol associated with RA treatment does not seem to confer a higher CV risk [61-63].

Patients with RA tended to have a lower likelihood of achieving therapeutic LDL levels after statin use. Increased erythrocyte sedimentation rate (ESR) is associated with a lower likelihood of achieving LDL targets, which underscores the importance of disease activity control in risk factor modification [64].

Close relationship between RA and CVD is mainly explained by the similarities in the inflammatory and immunologic responses [65].

Chronic systemic inflammation can promote endothelial cell activation and vascular dysfunction, which leads to decreased blood vessel compliance and atheroma formation, *i.e.* systemic inflammation accelerates development of atherosclerosis and heart disease.

The role of T lymphocytes is crucial in both RA and heart disease [66, 67]. HLA-DRB1, which is the major risk gene for RA, predisposes to RA by promoting the selection and survival of auto reactive CD4+ T cells. HLA-DRB1 alleles are also associated with increased risk of MI and various forms of non-RA-associated heart disease [68, 69]. As in heart disease, T lymphocytes isolated from the joints of RA-subjects have enhanced production of interferon- γ and interleukin-17, which presumably mediate chronic inflammation [70, 71].

Structural and Functional Changes of Myocardium in RA

Patients with RA are more likely to have abnormal LV geometry (higher LV mass and LV hypertrophy) than healthy people without RA. These abnormalities are associated with an increased risk of CVD. There is a strong association between increased LV mass (seen in patients with RA) and incident HF (HR 1.4 per 10% increment, $P < 0.0001$) [72, 73].

Patients with RA with abnormal LV geometry are also significantly more likely to have LV concentric remodelling (OR 4.73, 95% CI 2.85-7.83), which is associated with a higher risk of incident CHD [72, 74].

Speckle-tracking echocardiography is an advanced echocardiographic modality for detection of myocardial changes during contraction and relaxation (*i.e.*, myocardial strain) [75, 76]. According to the results of a population-based study in 87 patients with RA speckle-tracking echocardiography revealed a reduction in LV and right ventricular strain in RA patients when compared with the general population, which correlated with markers of disease severity [77].

Relationships between RA Characteristics, Duration and CVD

The RA disease characteristics seem to have an impact both on the risk of CVD development and CV

mortality, with rheumatoid factor (RF) positivity and disease severity conferring the greatest risk [78, 79].

Positive RF is a significant predictor of CV events including HF all-cause and CV mortality among the general population, suggesting a role for antibodies in the pathogenesis of CVD [79, 80]. Among RF-negative subjects, after adjusting for age, sex, CHD, and CV risk factors, the increased risk of HF was no longer significant in a population-based cohort study but remained significant with a 2.5-fold increased risk among RF-positive subjects (adjusted HR 2.59, 95% CI 1.95-3.43) [22]. Severe extra-articular manifestations of disease are associated with a higher likelihood of developing HF (HR 3.1, 95% CI 1.9-5.1) even after adjustment for CV risk factors [25]. The presence of rheumatoid lung disease and RA vasculitis, as disease severity markers, has also been associated with a greater likelihood of CV death [78].

It seems that the increased CVD risk in RA may predate the clinical manifestations of the disease, with evidence of atherosclerosis and CHD predating the diagnosis [81]. After the RA diagnosis, the relationship between the disease duration and CVD outcomes is less clear. The risk of DD in RA patients may be associated with the duration of disease: in population-based cohort studies there was shown that after adjusting for CV risk factors, there was a significant association between the duration of the disease and DD (OR 3.2, 95% CI 1.8-5.4) [82, 83].

Clinical Manifestations of CVD in RA Patients

It was shown that RA patients are less likely to have angina pectoris as a manifestation of CHD (OR 0.58, 95% CI 0.34-0.99), more likely to have silent MI (OR 5.86, 95% CI 1.29-26.64) compared with the general population, and less likely to have typical ECG changes at presentation [54, 84].

The difference in clinical presentation may contribute to delays in the recognition and treatment of patients with RA and emphasizes the importance of a high index of suspicion in these patients.

Typical clinical features of HF are less likely to be evident at presentation in patients with RA. Studies showed that they are less likely to have dyspnea on exertion, orthopnea, or paroxysmal nocturnal dyspnea at presentation. Patients with RA in this study were also more likely to have rales compared with non-RA subjects and less likely to have elevated BP at presentation [23].

The Role of Laboratory Markers: Brain Natriuretic Peptide (BNP) and Cardiac Troponin (cTn)

BNP is an important and prognostic biomarker of HF which is released mainly in heart ventricles and atria as a result to an increase in volume or pressure in heart chambers. Herewith, it was shown that BNP release has no circadian rhythm [29].

In general population BNP is used as a screening tool for LV DD detection, *i.e.* it may reveal asymptomatic patients with HF [85, 86].

There is no definite approach for BNP use in HF during RA. Harney SMJ *et al.* showed that BNP may be a potential beneficial method for HF screening [87]. Nevertheless, there is a need in larger studies to confirm this observation.

There is evidence that patients with no CVD history had higher BNP levels than healthy control subjects. Patients with active RA had higher levels of BNP than those with moderate or no activity, which suggests possibility of direct cardiodepressive effect of inflammatory cytokines [88].

In patients without clinical CVD, those with RA were more likely to have elevated BNP levels than non-RA subjects (16% vs 9%, $P < 0.001$). Patients with RA with abnormal BNP are more likely to have LV DD compared with those with normal BNP, but the specificity compared with non-RA patients (89% vs 94%, $P = 0.02$) and the positive predictive value (25%) of elevated BNP in patients with RA is low (25%) and is, therefore, not a good screening tool [89]. The duration of RA and CRP levels is independently associated with N-terminal proBNP [90].

In RA patients without HF high sensitive cTn-I is elevated independently of CV risk profile and inflammatory markers, which may suggest subclinical, silent damage of myocardium in these patients [91].

Prognosis and Outcome

The prognosis in RA patients with HF is worse than in those subjects without RA. In a community-based cohort study by Davis JM 3rd *et al.*, the 30-day mortality rate following the onset of HF was higher for RA compared to non-RA subjects (at 15.5% vs 6.6%, respectively ($p = 0.001$)). The 1-year mortality rate following HF remained higher for RA compared to non-RA subjects at 35% vs 19.3%, respectively ($p = 0.01$). After adjusting for age, sex, and calendar year, RA

subjects experienced a 2.39-fold higher risk of death 30 days following onset of HF compared to non-RA subjects (HR 2.39, 95% CI 1.36-4.18). At 1 year, this mortality difference was similar but less pronounced (adjusted HR 2.02, 95% CI 1.40-2.90). After also adjusting for use of CV medications and CHD, the excess 1-year mortality was similar (HR 1.89, 95% CI 1.26-2.84). Among those who survived the first year after onset of HF, there was no difference in overall survival between RA and non-RA subjects with HF in the subsequent years [23].

RA patients with HF seemed to have less aggressive control of HF and CV risk factors. In particular, these patients were administered first-line medications for HF treatment (ACE-inhibitors and β -blockers) less frequently compared to non-RA subjects: ACE inhibitors (15% vs 30%) and β -blockers (10% vs 23%) [23].

SUMMARY

CV system involvement is an important co-morbidity in rheumatic conditions which is accompanied by high mortality rates. In particular, HF is best described in RA and mostly is manifested by DD. In patients with RA the risk of HF is almost 2 times higher than in general population, and this risk is not explained entirely by traditional CV risk factors.

Speckle-tracking echocardiography can be useful in detecting early myocardial changes in RA-subjects.

BNP is an important clinical and prognostic marker of HF, but there are no final data concerning the screening value of BNP in patients with RA and HF. In patients with RA the typical clinical manifestations of HF differ from that in general population and have some features which are not well studied.

Both prognosis and outcome of RA patients with HF are worse than in non-RA subjects.

Summarizing all these key points it becomes clear, that up to date there is no definitely understanding of HF features in RA, identification and early detection of which will improve the prognosis of these patients via early treatment. And there is still a need in further and larger studies in this field.

REFERENCES

- [1] Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of

- observational studies. *Arthritis Rheum* 2008; 59(12): 1690-7. <https://doi.org/10.1002/art.24092>
- [2] Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. *Am J Med* 2008; 121(10 Suppl 1): S9-14. <https://doi.org/10.1016/j.amjmed.2008.06.011>
- [3] Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, *et al.* Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. *Arthritis Rheum* 2006; 54(1): 60-7. <https://doi.org/10.1002/art.21560>
- [4] Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. *J Rheumatol* 2003; 30(6): 1196-202.
- [5] Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. *Am J Med* 1975; 58(2): 243-64. [https://doi.org/10.1016/0002-9343\(75\)90575-6](https://doi.org/10.1016/0002-9343(75)90575-6)
- [6] Buss SJ, Wolf D, Korosoglou G, Max R, Weiss CS, Fischer C, *et al.* Myocardial left ventricular dysfunction in patients with systemic lupus erythematosus: new insights from tissue Doppler and strain imaging. *J Rheumatol* 2010; 37(1): 79-86. <https://doi.org/10.3899/jrheum.090043>
- [7] Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. *Arthritis Rheum* 2009; 61(10): 1396-402. <https://doi.org/10.1002/art.24537>
- [8] Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. *Arthritis Care Res (Hoboken)* 2011; 63(4): 550-6. <https://doi.org/10.1002/acr.20408>
- [9] Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. *Ann Rheum Dis* 2009; 68(7): 1131-5. <https://doi.org/10.1136/ard.2008.094839>
- [10] Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol* 2006; 33(11): 2167-72.
- [11] Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. *Ann Rheum Dis* 2013; 72(2): 211-6. <https://doi.org/10.1136/annrheumdis-2011-201194>
- [12] Mc Carey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. *Clin Exp Rheumatol* 2009; 27(4 Suppl55): S124-6.
- [13] Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, *et al.* Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. *Arthritis Rheum* 2011; 63(11): 3294-304. <https://doi.org/10.1002/art.30581>
- [14] Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. *The Lancet* 2010; vol. 376, 9746. 1094-1108.
- [15] Spector TD. Rheumatoid arthritis. *Rheum Dis Clin North Am* 1990; 16(3): 513-37.
- [16] Atzeni F, Sarzi-Puttini P. Early rheumatoid arthritis. *Reumatismo* 2007; 59: 100-117.
- [17] Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2007; 21: 871-83. <https://doi.org/10.1016/j.berh.2007.05.003>
- [18] Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. *Rheumatology* 2006; 45: iv4-iv7. <https://doi.org/10.1093/rheumatology/kei313>
- [19] John H, Toms TE, Kitas GD. Rheumatoid arthritis: is it a coronary heart disease equivalent? *Curr Opin Cardiol* 2011; 26: 327-333. <https://doi.org/10.1097/HCO.0b013e32834703b5>
- [20] Mann DL. Mechanisms and models in heart failure: a combinatorial approach. *Circulation* 1999; 100: 999-1008. <https://doi.org/10.1161/01.CIR.100.9.999>
- [21] Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. *Circ Res* 2002; 91: 988-98. <https://doi.org/10.1161/01.RES.0000043825.01705.1B>
- [22] Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, *et al.* The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. *Arthritis Rheum* 2005; 52(2): 412-20. <https://doi.org/10.1002/art.20855>
- [23] Davis JM 3rd, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. *Arthritis Rheum* 2008; 58(9): 2603-11. <https://doi.org/10.1002/art.23798>
- [24] Crowson CS, Nicola PJ, Kremers HM, O'Fallon WM, Therneau TM, Jacobsen SJ, *et al.* How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? *Arthritis Rheum* 2005; 52(10): 3039-44. <https://doi.org/10.1002/art.21349>
- [25] Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. *J Rheumatol* 2003; 30(1): 36-40.
- [26] Wolfe F, Michaud K. Heart failure in rheumatoid arthritis. rates, predictors, and the effect of antitumor necrosis factor therapy. *Am J Med* 2004; 116(5): 305-311. <https://doi.org/10.1016/j.amjmed.2003.09.039>
- [27] Alpaslan M, Onrat E, Evcik D. Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. *Clin Rheumatol* 2003; 22(2): 84-8. <https://doi.org/10.1007/s10067-002-0677-y>
- [28] Di Franco M, Paradiso M, Mammarella A, Paoletti V, Labbadia G, Coppotelli L, *et al.* Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. *Ann Rheum Dis* 2000; 59(3): 227-9. <https://doi.org/10.1136/ard.59.3.227>
- [29] Jensen KT, Carstens J, Ivarsen P, Pedersen EB. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. *Scand J Clin Lab Invest* 1997; 57(6): 529-40. <https://doi.org/10.3109/00365519709084604>
- [30] Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, *et al.* Progression of left ventricular diastolic dysfunction and risk of heart failure. *JAMA* 2011; 306(8): 856-63. <https://doi.org/10.1001/jama.2011.1201>
- [31] Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, *et al.* Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. *Circulation* 2011; 124(1): 24-30. <https://doi.org/10.1161/CIRCULATIONAHA.110.979203>
- [32] Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly. The

- cardiovascular health study. *J Am Coll Cardiol* 2001; 37(4): 1042-8.
[https://doi.org/10.1016/S0735-1097\(01\)01110-X](https://doi.org/10.1016/S0735-1097(01)01110-X)
- [33] Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, *et al*. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. *Circulation* 2002; 105(16): 1928-33.
<https://doi.org/10.1161/01.CIR.0000015076.37047.D9>
- [34] Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003; 289(2): 194-202.
<https://doi.org/10.1001/jama.289.2.194>
- [35] Butler J. Risk factors for heart failure. In: Hosenpud JD and Greenberg BH, editors. *Congestive Heart Failure*. 3rd ed. Pa, USA: Lippincott Williams & Wilkins, Philadelphia 2007; p. 263.
- [36] van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, *et al*. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. *Eur Heart J* 2006; 27: 2346-52.
<https://doi.org/10.1093/eurheartj/ehl230>
- [37] Tang WH, Katz R, Brennan ML, Aviles RJ, Tracy RP, Psaty BM, *et al*. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. *Am J Cardiol*. 2009 May 1; 103(9): 1269-1274.
<https://doi.org/10.1016/j.amjcard.2009.01.026>
- [38] Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, *et al*. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. *N Engl J Med*. 2007 Jul 5; 357(1): 28-38. Epub 2007 Jun 5.
<https://doi.org/10.1056/NEJMoa073394>
- [39] Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham heart study. *Ann Intern Med*. 2003 Jan 7; 138(1): 10-6.
<https://doi.org/10.7326/0003-4819-138-1-200301070-00006>
- [40] He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. *Arch Intern Med* 2001 Apr 9; 161(7): 996-1002.
<https://doi.org/10.1001/archinte.161.7.996>
- [41] Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, *et al*. Obesity and the risk of heart failure. *N Engl J Med* 2002 Aug 1; 347(5): 305-13.
<https://doi.org/10.1056/NEJMoa020245>
- [42] Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. *JAMA* 2001 Apr 18; 285(15): 1971-7.
<https://doi.org/10.1001/jama.285.15.1971>
- [43] Djousse L, Gaziano JM. Alcohol consumption and risk of heart failure in the Physicians' health study I. *Circulation* 2007; 115: 34-39.
<https://doi.org/10.1161/CIRCULATIONAHA.106.661868>
- [44] Djousse L, Gaziano JM. Alcohol consumption and heart failure: a systematic review. *Curr Atheroscler Rep* 2008; 10(2): 117-20.
<https://doi.org/10.1007/s11883-008-0017-z>
- [45] Kalogeropoulos A, Georgiopoulos V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, *et al*. Epidemiology of incident heart failure in a contemporary elderly cohort the health, aging, and body composition study. *Arch Intern Med* 2009 Apr 13; 169(7): 708-15.
<https://doi.org/10.1001/archinternmed.2009.40>
- [46] Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. *Am J Hypertens* 2003; 16(11 Pt 1): 938-44.
[https://doi.org/10.1016/S0895-7061\(03\)01015-X](https://doi.org/10.1016/S0895-7061(03)01015-X)
- [47] Sundström J, Lind L, Vessby B, Andrén B, Aro A, Lithell HO. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. *Circulation* 2001; 103: 836-841.
<https://doi.org/10.1161/01.CIR.103.6.836>
- [48] Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol* 1993 Oct; 22(4 Suppl A): 6A-13A.
[https://doi.org/10.1016/0735-1097\(93\)90455-A](https://doi.org/10.1016/0735-1097(93)90455-A)
- [49] Dhingra R, Sesso HD, Kenchaiah S, Gaziano JM. Differential effects of lipids on the risk of heart failure and coronary heart disease: the Physicians' health study. *Am Heart J* 2008; 155(5): 869-875.
<https://doi.org/10.1016/j.ahj.2007.12.023>
- [50] Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. *Kelley's Textbook of rheumatology*. 7th ed. Philadelphia: W.B. Saunders 2005: 996-1042.51.
- [51] Harris ED. Clinical features of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. *Kelley's Textbook of rheumatology*. 7th ed. Philadelphia: WB Saunders 2005: 1043-78.
- [52] Kuder SA, Peshimam AZ, Agraharam S. Environmental risk factors for rheumatoid arthritis. *Rev Environ Health* 2002; 17: 307-15.
<https://doi.org/10.1515/REVEH.2002.17.4.307>
- [53] Mikuls TR, Cerhan JR, Criswell LA, Merlino L, Mudano AS, Burma M, *et al*. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheum* 2002; 46: 83-91.
[https://doi.org/10.1002/1529-0131\(200201\)46:1<83::AID-ART10042>3.0.CO;2-D](https://doi.org/10.1002/1529-0131(200201)46:1<83::AID-ART10042>3.0.CO;2-D)
- [54] Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, *et al*. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2005; 52(2): 402-11.
<https://doi.org/10.1002/art.20853>
- [55] Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. *Arthritis Rheum* 2004; 50(11): 3444-9.
<https://doi.org/10.1002/art.20636>
- [56] Crowson CS, Therneau TM, Davis JM 3rd, Roger VL, Matteson EL, Gabriel SE. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. *Arthritis Rheum* 2013; 65:2562-6.
- [57] Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. *Joint Bone Spine* 2011; 78(2): 179-83.
<https://doi.org/10.1016/j.jbspin.2010.07.016>
- [58] Gonzalez A, Maradit-Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, *et al*. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? *Ann Rheum Dis* 2008; 67(1): 64-9.
<https://doi.org/10.1136/ard.2006.059980>
- [59] Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, *et al*. Lipid paradox in rheumatoid arthritis. The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. *Ann Rheum Dis* 2011; 70(3): 482-7.
<https://doi.org/10.1136/ard.2010.135871>
- [60] Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. *Arch Intern Med* 2005; 165(14): 1624-9.
<https://doi.org/10.1001/archinte.165.14.1624>

- [61] Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. *Ann Rheum Dis* 2009; 68(4): 460-9. <https://doi.org/10.1136/ard.2008.101964>
- [62] Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. *Semin Arthritis Rheum* 1992; 22(3): 172-8. [https://doi.org/10.1016/0049-0172\(92\)90017-8](https://doi.org/10.1016/0049-0172(92)90017-8)
- [63] Steiner G, Urowitz MB. Lipid in patients with rheumatoid arthritis: mechanisms and the impact of treatment. *Semin Arthritis Rheum* 2009; 38(5): 372-81. <https://doi.org/10.1016/j.semarthrit.2008.01.015>
- [64] Myasoedova E, Gabriel SE, Green AB, Matteson EL, Crowson CS. The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: results from a population-based study. *Arthritis Care Res (Hoboken)* 2013; 65: 1592-9. <https://doi.org/10.1002/acr.22029>
- [65] Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. *Circulation* Nov 23; 1999; 100(21): 2124-2126. <https://doi.org/10.1161/01.CIR.100.21.2124>
- [66] Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med* 2011; 17: 1410-22. <https://doi.org/10.1038/nm.2538>
- [67] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011; 365: 2205-19. <https://doi.org/10.1056/NEJMra1004965>
- [68] Paakkanen R, Lokki ML, Seppänen M, Tierala I, Nieminen MS, Sinisalo J. Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction. *Atherosclerosis* 2012; 221: 461-6. <https://doi.org/10.1016/j.atherosclerosis.2012.01.024>
- [69] Sun W, Cui Y, Zhen L, Huang L. Association between HLA-DRB1, HLADRQB1 alleles, and CD4(+)CD28(null) T cells in a Chinese population with coronary heart disease. *Mol Biol Rep* 2011; 38: 1675-9. <https://doi.org/10.1007/s11033-010-0279-8>
- [70] Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, *et al.* Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. *Circulation* 2009; 119: 1424-32. <https://doi.org/10.1161/CIRCULATIONAHA.108.827618>
- [71] Nistala K, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, *et al.* Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. *Proc Natl Acad Sci USA* 2010; 107: 14751-6. <https://doi.org/10.1073/pnas.1003852107>
- [72] Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, *et al.* The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol* 2008; 52(25): 2148-55. <https://doi.org/10.1016/j.jacc.2008.09.014>
- [73] Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, *et al.* Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. *Arthritis Rheum* 2009; 60(1): 22-9. <https://doi.org/10.1002/art.24148>
- [74] Myasoedova E, Davis JM 3rd, Crowson CS, Roger VL, Karon BL, Borgeson DD, *et al.* Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. *Arthritis Rheum* 2013; 65(7): 1713-8. <https://doi.org/10.1002/art.37949>
- [75] Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, *et al.* Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. *J Am Coll Cardiol* 2006; 47(4): 789-93. <https://doi.org/10.1016/j.jacc.2005.10.040>
- [76] Sitia S, Tomasoni L, Cicala S, Atzeni F, Ricci C, Gaeta M, *et al.* Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. *Int J Cardiol* 2012; 160(1): 8-14. <https://doi.org/10.1016/j.ijcard.2011.03.012>
- [77] Fine N, Crowson CS, Lin G. Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography. *Ann Rheum Dis* 2013. [Epub ahead of print]. <https://doi.org/10.1136/annrheumdis-2012-eular.2041>
- [78] Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005; 52(3): 722-32. <https://doi.org/10.1002/art.20878>
- [79] Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. *Ann Rheum Dis* 2010; 69(9): 1649-54. <https://doi.org/10.1136/ard.2009.110536>
- [80] Liang KP, Kremers HM, Crowson CS, Snyder MR, Therneau TM, Roger VL, *et al.* Autoantibodies and the risk of cardiovascular events. *J Rheumatol* 2009; 36(11): 2462-9. <https://doi.org/10.3899/jrheum.090188>
- [81] Kerola AM, Kauppi MJ, Kerola T, Nieminen TV. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? *Ann Rheum Dis* 2012; 71(10): 1606-15. <https://doi.org/10.1136/annrheumdis-2012-201334>
- [82] Levendoglu F, Temizhan A, Ugurlu H, Ozdemir A, Yazici M. Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. *Rheumatol Int* 2004; 24(3): 141-6. <https://doi.org/10.1007/s00296-003-0342-z>
- [83] Yavasoglu I, Senturk T, Onbasili A. Diastolic dysfunction in rheumatoid arthritis and duration of disease. *Rheumatol Int* 2008; 29(1): 113-4. <https://doi.org/10.1007/s00296-008-0625-5>
- [84] Södergren A, Stegmayr B, Lundberg V, Öhman ML, Wållberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. *Ann Rheum Dis* 2007; 66(2): 263-6. <https://doi.org/10.1136/ard.2006.052456>
- [85] Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, *et al.* Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. *Am Heart J* 2001; 141(3): 367-74. <https://doi.org/10.1067/mhj.2001.113215>
- [86] Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. *Circulation* 2004 Jun 29; 109(25): 3176-81. Epub 2004 Jun 7. <https://doi.org/10.1161/01.CIR.0000130845.38133.8F>
- [87] Harney SMJ, Timperley J, Daly C, Harin A, James T, Brown MA, *et al.* Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. *Ann Rheum Dis* 2006 Jan; 65(1): 136. <https://doi.org/10.1136/ard.2005.040634>

- [88] Armstrong DJ, Gardiner PV, O'Kane MJ. Rheumatoid arthritis patients with active disease and no history of cardiac pathology have higher brain natriuretic peptide (BNP) levels than patients with inactive disease or healthy control subjects. *Ulster Med J* 2010; 79 (2): 82-84.
- [89] Crowson CS, Myasoedova E, Davis JM 3rd, Roger VL, Karon BL, Borgeson D, *et al.* Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. *Arthritis Care Res (Hoboken)* 2011; 63(5): 729-34. <https://doi.org/10.1002/acr.20425>
- [90] Provan SA, Angel K, Odegard S, Mowinckel P, Atar D, Kvien TK. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. *Arthritis Res Ther* 2008; 10(3): R70. <https://doi.org/10.1186/ar2442>
- [91] Bradham WS, Bian A, Oeser A, Gebretsadik T, Shintani A, Solus J, *et al.* High-sensitivity cardiac troponin-I is elevated in patients with rheumatoid arthritis, independent of cardiovascular risk factors and inflammation. *PLoS One* 2012; 7(6): e38930. Epub 2012 Jun 28. <https://doi.org/10.1371/journal.pone.0038930>

Received on 30-09-2017

Accepted on 26-10-2017

Published on 02-11-2017

<http://dx.doi.org/10.15379/2410-2822.2017.04.02.02>

© 2017 Harutyun S. Hovhannisyan; Licensee Cosmos Scholars Publishing House.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License

(<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.